BackCue Biopharma Overview

Cue Biopharma Current Cash

Latest current cash for CUE: $16M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$16.38M
↑ 24.69% YoYΔ $3.24M vs prior year quarter

Peer average / median

Loading

Cue Biopharma Current Cash History

Loading

Cue Biopharma vs. peers: Current Cash Comparison

Loading

Cue Biopharma Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Cue Biopharma (CUE) FAQ

As of the most recent data (March 2026), CUE shows a current cash of $16M. That compares with $13M in the prior-year period — up 24.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CUE's current cash is now $16M (was $13M) — a 24.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Cue Biopharma is outperforming or lagging.

Tracking CUE's current cash over time shows whether Cue Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $16M That compares with $13M in the prior-year period — up 24.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Cue Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $16M) with ownership activity and broader fundamentals.

Cue Biopharma's current cash is $16M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.